Veralipride
Systematic (IUPAC) name | |
---|---|
2,3-dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide | |
Clinical data | |
Trade names | Agreal, Agradil |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | 66644-81-3 |
ATC code | N05AL06 (WHO) |
PubChem | CID 47979 |
ChemSpider | 43638 |
UNII | S7064109UD |
Chemical data | |
Formula | C17H25N3O5S |
Molar mass | 383.4625 g/mol |
| |
| |
(what is this?) (verify) |
Veralipride (Agreal, Agradil) is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause. It was first authorised for use in 1979. Veralipride has never gained approval in the United States.
In September 2006, it was withdrawn from the Spanish market. As a result, the European Commission referred the matter to the European Medicines Agency (EMA). On July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.[1]
See also
References
|
This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.